Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Fifty 410 vs FuturHealth

Fifty 410
Graded #94

Higher grade

vs+5.700000000000003
FuturHealth
Graded #215

Lower grade

The verdict

Fifty 410 takes it — 71.3/100 to 65.6/100.

Fifty 410 grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Fifty 410 is a direct-to-consumer weight-loss telehealth service offering personalized compounded semaglutide and tirzepatide prescribed by licensed providers and prepared by FDA-registered 503A and 503B…

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueFifty 410 +26
86
60
Dose & formulationFuturHealth +9
72
81
Clinical oversightFifty 410 +13
80
67
Labs & monitoringFuturHealth +8
53
61
FulfillmentFifty 410 +9
71
62
Contract termsFuturHealth +18
37
55
Fifty 410 · left barFuturHealth · right bar

The numbers

MetricFifty 410FuturHealth
WeighScore71.3/10065.6/100
GradeCC
Scorecard rank#94#215
Semaglutide$99/mo (all doses, compounded)$199/mo (compounded)
Tirzepatide$133/mo (starting dose, compounded)Not disclosed
CoverageCoverage not publishedCoverage not published
Brand-name accessCompounded onlyYes
Oral / sublingualInjection onlyYes
Fifty 410

Graded #94 · C

Strengths

  • Transparent public pricing from 99 dollars per month for semaglutide
  • No membership or subscription; pay only for what you need
  • Compounded by FDA-registered 503A and 503B pharmacies
  • Fast 24 to 48 hour provider review
  • Free one to two day shipping

Where it loses points

  • Does not bill insurance directly
  • Compounded GLP-1 is not an FDA-approved finished drug
  • Specific clinician credentials are not publicly disclosed
  • Served-states list is not published on the site
  • No branded GLP-1 options
FuturHealth

Graded #215 · C

Strengths

  • LegitScript Certified and HITRUST Certified
  • Brand-name and oral GLP-1s on one platform: Wegovy injection and pill, Zepbound, Mounjaro, Ozempic, and Foundayo
  • Early direct-to-consumer access to Foundayo (orforglipron), the new oral non-peptide GLP-1
  • Bundled registered-dietitian nutrition guidance — uncommon among pure-Rx telehealths

Where it loses points

  • Active lawsuit (Wilson v. FuturHealth) alleging unauthorized access to G-Plans subscriber data
  • BBB complaints describe recurring charges without medication received — confirm cancellation flow first
  • Pharmacy partners described only as 'licensed, U.S.-based' with no specific 503A/503B names
  • Pricing not shown until after the qualification questionnaire or portal login
  • Front-end brand built on SteadyMD and OpenLoop infrastructure, not a first-party prescriber

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard